Morgan Stanley’s GRI Bio GRI Stock Holding History

Morgan Stanley’s Portfolio GRI Stock Details GRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.5K	Buy	+8,737	New	+$19.4K	﹤0.01%	6907
2023 Q1	–	Hold	0	–	-$26	–	7759
2022 Q4	–	Hold	0	–	–	–	7755
2022 Q3	–	Hold	0	–	–	–	7763
2022 Q2	–	Hold	0	–	–	–	7867
2022 Q1	–	Hold	0	–	–	–	7630
2021 Q4	–	Hold	0	–	–	–	7301
2021 Q3	–	Hold	0	–	–	–	7116

Other funds holding GRI

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Morgan Stanley's GRI Position: Q2 2026 in Review

Morgan Stanley opened a new position in GRI Bio (GRI) in Q2 2026: 8,737 shares worth $15.5K. The stake represents ﹤0.01% of the portfolio and ranks #6907 among its holdings.

11 funds tracked by Wall St. Rank hold GRI as of Q2 2026.

Morgan Stanley held 8,737 shares of GRI Bio worth $15.5K as of Q2 2026.
GRI Bio was a new Morgan Stanley position in Q2 2026.
GRI Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6907 holding.
11 funds tracked by Wall St. Rank held GRI Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.